APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Axillary Hyperhidrosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Axillary Hyperhidrosis Drug Market Outlook and Growth Opportunities 2026

Report ID 173968530422 December 2025193 pages

Choose your research edition.

Industry ResearchAxillary Hyperhidrosis Drug Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Axillary Hyperhidrosis Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Axillary Hyperhidrosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Axillary Hyperhidrosis Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Axillary Hyperhidrosis Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Axillary Hyperhidrosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Axillary Hyperhidrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Axillary Hyperhidrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Axillary Hyperhidrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Axillary Hyperhidrosis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Axillary Hyperhidrosis Drug market include GlaxoSmithKline Plc, TheraVida Inc, Dr. August Wolff GmbH & Co KG Arzneimittle, Dermira Inc, Brickell Biotech Inc and Allergan Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Axillary Hyperhidrosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Axillary Hyperhidrosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Axillary Hyperhidrosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Axillary Hyperhidrosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Axillary Hyperhidrosis Drug Segment by Company

GlaxoSmithKline Plc

TheraVida Inc

Dr. August Wolff GmbH & Co KG Arzneimittle

Dermira Inc

Brickell Biotech Inc

Allergan Plc

Axillary Hyperhidrosis Drug Segment by Type

Botulinum ToxinA

Glycopyrronium Tosylate

Glycopyrrolate

Others

Axillary Hyperhidrosis Drug Segment by Application

Home Care

Hospital

Clinic

Axillary Hyperhidrosis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Axillary Hyperhidrosis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Axillary Hyperhidrosis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Axillary Hyperhidrosis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Axillary Hyperhidrosis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Axillary Hyperhidrosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Axillary Hyperhidrosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Axillary Hyperhidrosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Axillary Hyperhidrosis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Axillary Hyperhidrosis Drug industry.

Chapter 3: Detailed analysis of Axillary Hyperhidrosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Axillary Hyperhidrosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Axillary Hyperhidrosis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Axillary Hyperhidrosis Drug Industry Trends Table 2. Axillary Hyperhidrosis Drug Industry Drivers Table 3. Axillary Hyperhidrosis Drug Industry Opportunities and Challenges Table 4. Axillary Hyperhidrosis Drug Industry Restraints Table 5. Global Axillary Hyperhidrosis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Axillary Hyperhidrosis Drug Revenue Share by Company (2021-2026) Table 7. Global Axillary Hyperhidrosis Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Axillary Hyperhidrosis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Axillary Hyperhidrosis Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Axillary Hyperhidrosis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Axillary Hyperhidrosis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Axillary Hyperhidrosis Drug Company, Product Type & Application Table 13. Global Axillary Hyperhidrosis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Axillary Hyperhidrosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Botulinum ToxinA Table 18. Significant Companies of Glycopyrronium Tosylate Table 19. Significant Companies of Glycopyrrolate Table 20. Significant Companies of Others Table 21. Global Axillary Hyperhidrosis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Axillary Hyperhidrosis Drug Sales Volume by Type (2021-2026) & (k units) Table 23. Global Axillary Hyperhidrosis Drug Sales Volume by Type (2027-2032) & (k units) Table 24. Global Axillary Hyperhidrosis Drug Sales Volume Share by Type (2021-2026) Table 25. Global Axillary Hyperhidrosis Drug Sales Volume Share by Type (2027-2032) Table 26. Global Axillary Hyperhidrosis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Axillary Hyperhidrosis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Axillary Hyperhidrosis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Axillary Hyperhidrosis Drug Sales Value Share by Type (2021-2026) Table 30. Global Axillary Hyperhidrosis Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Home Care Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Global Axillary Hyperhidrosis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Axillary Hyperhidrosis Drug Sales Volume by Application (2021-2026) & (k units) Table 36. Global Axillary Hyperhidrosis Drug Sales Volume by Application (2027-2032) & (k units) Table 37. Global Axillary Hyperhidrosis Drug Sales Volume Share by Application (2021-2026) Table 38. Global Axillary Hyperhidrosis Drug Sales Volume Share by Application (2027-2032) Table 39. Global Axillary Hyperhidrosis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Axillary Hyperhidrosis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Axillary Hyperhidrosis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Axillary Hyperhidrosis Drug Sales Value Share by Application (2021-2026) Table 43. Global Axillary Hyperhidrosis Drug Sales Value Share by Application (2027-2032) Table 44. Global Axillary Hyperhidrosis Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Axillary Hyperhidrosis Drug Sales by Region (2021-2026) & (k units) Table 46. Global Axillary Hyperhidrosis Drug Sales Market Share by Region (2021-2026) Table 47. Global Axillary Hyperhidrosis Drug Sales by Region (2027-2032) & (k units) Table 48. Global Axillary Hyperhidrosis Drug Sales Market Share by Region (2027-2032) Table 49. Global Axillary Hyperhidrosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Axillary Hyperhidrosis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Axillary Hyperhidrosis Drug Sales Value Share by Region (2021-2026) Table 52. Global Axillary Hyperhidrosis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Axillary Hyperhidrosis Drug Sales Value Share by Region (2027-2032) Table 54. Global Axillary Hyperhidrosis Drug Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Axillary Hyperhidrosis Drug Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Axillary Hyperhidrosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Axillary Hyperhidrosis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Axillary Hyperhidrosis Drug Sales by Country (2021-2026) & (k units) Table 59. Global Axillary Hyperhidrosis Drug Sales Market Share by Country (2021-2026) Table 60. Global Axillary Hyperhidrosis Drug Sales by Country (2027-2032) & (k units) Table 61. Global Axillary Hyperhidrosis Drug Sales Market Share by Country (2027-2032) Table 62. Global Axillary Hyperhidrosis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Axillary Hyperhidrosis Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Axillary Hyperhidrosis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Axillary Hyperhidrosis Drug Sales Value Market Share by Country (2027-2032) Table 66. GlaxoSmithKline Plc Company Information Table 67. GlaxoSmithKline Plc Business Overview Table 68. GlaxoSmithKline Plc Axillary Hyperhidrosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. GlaxoSmithKline Plc Axillary Hyperhidrosis Drug Product Portfolio Table 70. GlaxoSmithKline Plc Recent Development Table 71. TheraVida Inc Company Information Table 72. TheraVida Inc Business Overview Table 73. TheraVida Inc Axillary Hyperhidrosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. TheraVida Inc Axillary Hyperhidrosis Drug Product Portfolio Table 75. TheraVida Inc Recent Development Table 76. Dr. August Wolff GmbH & Co KG Arzneimittle Company Information Table 77. Dr. August Wolff GmbH & Co KG Arzneimittle Business Overview Table 78. Dr. August Wolff GmbH & Co KG Arzneimittle Axillary Hyperhidrosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Dr. August Wolff GmbH & Co KG Arzneimittle Axillary Hyperhidrosis Drug Product Portfolio Table 80. Dr. August Wolff GmbH & Co KG Arzneimittle Recent Development Table 81. Dermira Inc Company Information Table 82. Dermira Inc Business Overview Table 83. Dermira Inc Axillary Hyperhidrosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Dermira Inc Axillary Hyperhidrosis Drug Product Portfolio Table 85. Dermira Inc Recent Development Table 86. Brickell Biotech Inc Company Information Table 87. Brickell Biotech Inc Business Overview Table 88. Brickell Biotech Inc Axillary Hyperhidrosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Brickell Biotech Inc Axillary Hyperhidrosis Drug Product Portfolio Table 90. Brickell Biotech Inc Recent Development Table 91. Allergan Plc Company Information Table 92. Allergan Plc Business Overview Table 93. Allergan Plc Axillary Hyperhidrosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Allergan Plc Axillary Hyperhidrosis Drug Product Portfolio Table 95. Allergan Plc Recent Development Table 96. Key Raw Materials Table 97. Raw Materials Key Suppliers Table 98. Axillary Hyperhidrosis Drug Distributors List Table 99. Axillary Hyperhidrosis Drug Customers List Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Axillary Hyperhidrosis Drug Product Image Figure 2. Global Axillary Hyperhidrosis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Axillary Hyperhidrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Axillary Hyperhidrosis Drug Sales (2021-2032) & (k units) Figure 5. Global Axillary Hyperhidrosis Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Axillary Hyperhidrosis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Botulinum ToxinA Image Figure 10. Glycopyrronium Tosylate Image Figure 11. Glycopyrrolate Image Figure 12. Others Image Figure 13. Global Axillary Hyperhidrosis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Axillary Hyperhidrosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Axillary Hyperhidrosis Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Axillary Hyperhidrosis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Axillary Hyperhidrosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Axillary Hyperhidrosis Drug Sales Value Share by Type (2021-2032) Figure 19. Home Care Image Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Global Axillary Hyperhidrosis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Axillary Hyperhidrosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Axillary Hyperhidrosis Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Axillary Hyperhidrosis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Axillary Hyperhidrosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Axillary Hyperhidrosis Drug Sales Value Share by Application (2021-2032) Figure 28. Global Axillary Hyperhidrosis Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Axillary Hyperhidrosis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Axillary Hyperhidrosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Axillary Hyperhidrosis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Axillary Hyperhidrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Axillary Hyperhidrosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Axillary Hyperhidrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Axillary Hyperhidrosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Axillary Hyperhidrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Axillary Hyperhidrosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Axillary Hyperhidrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Axillary Hyperhidrosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Axillary Hyperhidrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Axillary Hyperhidrosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Axillary Hyperhidrosis Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Axillary Hyperhidrosis Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Botulinum ToxinA
  • Glycopyrronium Tosylate
  • Glycopyrrolate
  • Others
Applications
  • Home Care
  • Hospital
  • Clinic
Companies covered
  • GlaxoSmithKline Plc
  • TheraVida Inc
  • Dr. August Wolff GmbH & Co KG Arzneimittle
  • Dermira Inc
  • Brickell Biotech Inc
  • Allergan Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Axillary Hyperhidrosis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Axillary Hyperhidrosis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Axillary Hyperhidrosis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Axillary Hyperhidrosis Drug Market Dynamics
  1. 2.1 Axillary Hyperhidrosis Drug Industry Trends
  2. 2.2 Axillary Hyperhidrosis Drug Industry Drivers
  3. 2.3 Axillary Hyperhidrosis Drug Industry Opportunities and Challenges
  4. 2.4 Axillary Hyperhidrosis Drug Industry Restraints
3 Axillary Hyperhidrosis Drug Market by Company
  1. 3.1 Global Axillary Hyperhidrosis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Axillary Hyperhidrosis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Axillary Hyperhidrosis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Axillary Hyperhidrosis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Axillary Hyperhidrosis Drug Company Ranking (2024-2026)
  6. 3.6 Global Axillary Hyperhidrosis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Axillary Hyperhidrosis Drug Company Product Type and Application
  8. 3.8 Global Axillary Hyperhidrosis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Axillary Hyperhidrosis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Axillary Hyperhidrosis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Axillary Hyperhidrosis Drug Market by Type
  1. 4.1 Axillary Hyperhidrosis Drug Type Introduction
  2. 4.1.1 Botulinum ToxinA
  3. 4.1.2 Glycopyrronium Tosylate
  4. 4.1.3 Glycopyrrolate
  5. 4.1.4 Others
  6. 4.2 Global Axillary Hyperhidrosis Drug Sales Volume by Type
  7. 4.2.1 Global Axillary Hyperhidrosis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Axillary Hyperhidrosis Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Axillary Hyperhidrosis Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Axillary Hyperhidrosis Drug Sales Value by Type
  11. 4.3.1 Global Axillary Hyperhidrosis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Axillary Hyperhidrosis Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Axillary Hyperhidrosis Drug Sales Value Share by Type (2021-2032)
5 Axillary Hyperhidrosis Drug Market by Application
  1. 5.1 Axillary Hyperhidrosis Drug Application Introduction
  2. 5.1.1 Home Care
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.2 Global Axillary Hyperhidrosis Drug Sales Volume by Application
  6. 5.2.1 Global Axillary Hyperhidrosis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Axillary Hyperhidrosis Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Axillary Hyperhidrosis Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Axillary Hyperhidrosis Drug Sales Value by Application
  10. 5.3.1 Global Axillary Hyperhidrosis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Axillary Hyperhidrosis Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Axillary Hyperhidrosis Drug Sales Value Share by Application (2021-2032)
6 Axillary Hyperhidrosis Drug Regional Sales and Value Analysis
  1. 6.1 Global Axillary Hyperhidrosis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Axillary Hyperhidrosis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Axillary Hyperhidrosis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Axillary Hyperhidrosis Drug Sales by Region (2027-2032)
  5. 6.3 Global Axillary Hyperhidrosis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Axillary Hyperhidrosis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Axillary Hyperhidrosis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Axillary Hyperhidrosis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Axillary Hyperhidrosis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Axillary Hyperhidrosis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Axillary Hyperhidrosis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Axillary Hyperhidrosis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Axillary Hyperhidrosis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Axillary Hyperhidrosis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Axillary Hyperhidrosis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Axillary Hyperhidrosis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Axillary Hyperhidrosis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Axillary Hyperhidrosis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Axillary Hyperhidrosis Drug Sales Value Share by Country, 2025 VS 2032
7 Axillary Hyperhidrosis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Axillary Hyperhidrosis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Axillary Hyperhidrosis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Axillary Hyperhidrosis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Axillary Hyperhidrosis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Axillary Hyperhidrosis Drug Sales by Country (2027-2032)
  6. 7.4 Global Axillary Hyperhidrosis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Axillary Hyperhidrosis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Axillary Hyperhidrosis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Axillary Hyperhidrosis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Axillary Hyperhidrosis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Axillary Hyperhidrosis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GlaxoSmithKline Plc
  2. 8.1.1 GlaxoSmithKline Plc Company Information
  3. 8.1.2 GlaxoSmithKline Plc Business Overview
  4. 8.1.3 GlaxoSmithKline Plc Axillary Hyperhidrosis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GlaxoSmithKline Plc Axillary Hyperhidrosis Drug Product Portfolio
  6. 8.1.5 GlaxoSmithKline Plc Recent Developments
  7. 8.2 TheraVida Inc
  8. 8.2.1 TheraVida Inc Company Information
  9. 8.2.2 TheraVida Inc Business Overview
  10. 8.2.3 TheraVida Inc Axillary Hyperhidrosis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 TheraVida Inc Axillary Hyperhidrosis Drug Product Portfolio
  12. 8.2.5 TheraVida Inc Recent Developments
  13. 8.3 Dr. August Wolff GmbH & Co KG Arzneimittle
  14. 8.3.1 Dr. August Wolff GmbH & Co KG Arzneimittle Company Information
  15. 8.3.2 Dr. August Wolff GmbH & Co KG Arzneimittle Business Overview
  16. 8.3.3 Dr. August Wolff GmbH & Co KG Arzneimittle Axillary Hyperhidrosis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Dr. August Wolff GmbH & Co KG Arzneimittle Axillary Hyperhidrosis Drug Product Portfolio
  18. 8.3.5 Dr. August Wolff GmbH & Co KG Arzneimittle Recent Developments
  19. 8.4 Dermira Inc
  20. 8.4.1 Dermira Inc Company Information
  21. 8.4.2 Dermira Inc Business Overview
  22. 8.4.3 Dermira Inc Axillary Hyperhidrosis Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Dermira Inc Axillary Hyperhidrosis Drug Product Portfolio
  24. 8.4.5 Dermira Inc Recent Developments
  25. 8.5 Brickell Biotech Inc
  26. 8.5.1 Brickell Biotech Inc Company Information
  27. 8.5.2 Brickell Biotech Inc Business Overview
  28. 8.5.3 Brickell Biotech Inc Axillary Hyperhidrosis Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Brickell Biotech Inc Axillary Hyperhidrosis Drug Product Portfolio
  30. 8.5.5 Brickell Biotech Inc Recent Developments
  31. 8.6 Allergan Plc
  32. 8.6.1 Allergan Plc Company Information
  33. 8.6.2 Allergan Plc Business Overview
  34. 8.6.3 Allergan Plc Axillary Hyperhidrosis Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Allergan Plc Axillary Hyperhidrosis Drug Product Portfolio
  36. 8.6.5 Allergan Plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Axillary Hyperhidrosis Drug Value Chain Analysis
  2. 9.1.1 Axillary Hyperhidrosis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Axillary Hyperhidrosis Drug Sales Mode & Process
  6. 9.2 Axillary Hyperhidrosis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Axillary Hyperhidrosis Drug Distributors
  9. 9.2.3 Axillary Hyperhidrosis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst